Jefferies Financial Group Inc. Acquires Shares of 3,031,374 Certara, Inc. $CERT

Jefferies Financial Group Inc. acquired a new stake in Certara, Inc. (NASDAQ:CERT) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 3,031,374 shares of the company’s stock, valued at approximately $26,706,000. Jefferies Financial Group Inc. owned about 1.90% of Certara at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of CERT. Wasatch Advisors LP boosted its holdings in shares of Certara by 45.7% in the 2nd quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock valued at $158,335,000 after buying an additional 4,244,230 shares in the last quarter. Deerfield Management Company L.P. boosted its holdings in shares of Certara by 71.7% in the 3rd quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock valued at $82,357,000 after buying an additional 2,813,438 shares in the last quarter. Fort Washington Investment Advisors Inc. OH boosted its holdings in shares of Certara by 133.4% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 2,272,823 shares of the company’s stock valued at $20,024,000 after buying an additional 1,299,109 shares in the last quarter. Ameriprise Financial Inc. boosted its holdings in shares of Certara by 27.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after buying an additional 1,165,064 shares in the last quarter. Finally, Brown Brothers Harriman & Co. boosted its holdings in shares of Certara by 34.8% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 3,764,034 shares of the company’s stock valued at $45,996,000 after buying an additional 972,669 shares in the last quarter. 73.96% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on CERT shares. Leerink Partners reiterated an “outperform” rating and set a $10.00 target price on shares of Certara in a research report on Thursday, February 26th. Craig Hallum cut their target price on Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a research report on Tuesday, May 12th. Robert W. Baird cut their target price on Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 12th. KeyCorp cut their target price on Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, April 13th. Finally, Morgan Stanley cut their target price on Certara from $11.00 to $10.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and a consensus price target of $8.85.

Certara Trading Up 1.4%

Shares of Certara stock opened at $5.24 on Friday. Certara, Inc. has a 1 year low of $4.45 and a 1 year high of $13.88. The company has a debt-to-equity ratio of 0.28, a quick ratio of 1.88 and a current ratio of 1.88. The company has a market capitalization of $815.16 million, a P/E ratio of -52.40 and a beta of 1.53. The company’s fifty day moving average is $5.80 and its two-hundred day moving average is $7.58.

Certara (NASDAQ:CERT) last issued its quarterly earnings data on Monday, May 11th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The business had revenue of $106.92 million for the quarter, compared to analysts’ expectations of $106.13 million. During the same period in the previous year, the business posted $0.14 earnings per share. The company’s revenue for the quarter was up .8% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Analysts forecast that Certara, Inc. will post 0.29 earnings per share for the current year.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.